title: Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
authors: a Division of Hematology and Medical Oncology , Center for Lymphoma and Myeloma, Weill Cornell Medical College , New York , NY , USA.
authors: Richard R
authors: RR
authors: Furman
authors: b Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
authors: Ying
authors: Y
authors: Luan
authors: b Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
authors: Elizabeth
authors: E
authors: Bilotti
authors: b Pharmacyclics LLC, an AbbVie Company , Sunnyvale , CA , USA.
authors: Thorsten
authors: T
authors: Graef
mesh_terms: D000077329:Agammaglobulinaemia Tyrosine Kinase; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers; D001706:Biopsy; D006801:Humans; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D019233:Retreatment; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase